This site is intended for Healthcare professionals only.

Lupin gets EIR from USFDA for Pithampur facility

Lupin gets EIR from USFDA for Pithampur facility

New Delhi: Drug firm Lupin said it has received an Establishment Inspection Report (EIR) from the US health regulator for its Pithampur, Unit 1 manufacturing facility in Madhya Pradesh.

The inspection was conducted in July 2017, it said in a BSE filing.

USFDA gives EIR on the closure of inspection of an establishment that is the subject of an FDA or FDA-contracted inspection.

In November last, Lupin had received a warning letter from USFDA (US Food and Drug Administration) for its manufacturing facilities in Goa and Pithampur.



Source: PTI
0 comment(s) on Lupin gets EIR from USFDA for Pithampur facility

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted